Department of Neurointervention and Neurocritical Care, Dalian Central Hospital Affiliated to Dalian University of Technology, Dalian, China.
Department of Neurology, The Second Hospital of Dalian Medical University, Shahekou District, Liaoning, China.
Brain Behav. 2024 Nov;14(11):e70119. doi: 10.1002/brb3.70119.
Mechanical thrombectomy (MT) is standard of care for acute cerebral infarction (ACI) due to large vessel occlusions. However, its clinical efficacy in patients with ACI due to distal medium vessel occlusions (DMVOs) remains unclear. This study evaluates the efficacy and safety of MT in patients with ACI due to DMVOs.
Totally, 306 patients with ACI at a very early stage were assigned into DMVOs-MT, M1-MT, and DMVOs-intravenous thrombolysis (IVT) groups. These groups were compared regarding baseline data, recanalization rate, location of vessel occlusions, number of thrombectomy, first-pass recanalization, mRS scores, NIHSS scores, 90-day mRS scores, incidence of adverse events, and mortality. Risk factors for poor prognosis of patients with DMVOs following MT were analyzed.
DMVOs-MT and M1-MT groups showed comparable first-pass recanalization rates, recanalization rates, and NIHSS score reduction ratios, with marked differences in location of vessel occlusions. Versus DMVOs-IVT, DMVOs-MT had increased differences between pre- and post-treatment NIHSS scores and between pre-treatment NIHSS scores and NIHSS scores at discharge and elevated NIHSS reduction ratios. The poor prognosis rate of DMVOs-MT group was insignificantly different from that of M1-MT group but lower than that of DMVOs-IVT group. Adverse events and mortality incidences were comparable among the three groups. Diabetes, first-pass recanalization, and pre-treatment NIHSS scores were independent risk factors for poor prognosis in DMVO patients after MT.
MT is as effective and safe in patients with DMVOs as in patients with M1 occlusions. In patients with DMVOs, MT has higher efficacy and safety than IVT.
机械取栓(MT)是治疗大血管闭塞性急性脑梗死(ACI)的标准治疗方法。然而,其在治疗远端中等血管闭塞(DMVOs)所致 ACI 的临床疗效尚不清楚。本研究评估了 MT 在治疗 DMVOs 所致 ACI 中的疗效和安全性。
共纳入 306 例 ACI 超早期患者,分为 DMVOs-MT 组、M1-MT 组和 DMVOs-静脉溶栓(IVT)组。比较三组的基线资料、再通率、血管闭塞部位、取栓次数、首次通过再通率、mRS 评分、NIHSS 评分、90 天 mRS 评分、不良事件发生率及死亡率。分析 MT 治疗后 DMVOs 患者预后不良的危险因素。
DMVOs-MT 组和 M1-MT 组的首次通过再通率、再通率及 NIHSS 评分降低率相似,但血管闭塞部位不同。与 DMVOs-IVT 组相比,DMVOs-MT 组治疗前后 NIHSS 评分差值、治疗前 NIHSS 评分与出院时 NIHSS 评分差值及 NIHSS 评分降低率均明显增大。DMVOs-MT 组预后不良率与 M1-MT 组无显著差异,但低于 DMVOs-IVT 组。三组不良事件及死亡率发生率无显著差异。糖尿病、首次通过再通及治疗前 NIHSS 评分是 MT 治疗后 DMVO 患者预后不良的独立危险因素。
MT 治疗 DMVOs 与治疗 M1 段闭塞同样有效且安全。在 DMVOs 患者中,MT 较 IVT 更有效且安全。